BOSTON, Oct. 13, 2022 (GLOBE NEWSWIRE) — PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology firm advancing the following era of oligonucleotide therapies with the objective of remodeling the remedy of extreme neuromuscular and neurological illnesses, introduced the presentation of knowledge from its Duchenne muscular dystrophy program. The information are featured in a poster at the twenty seventh International Hybrid Annual Congress of the World Muscle Society going down in Halifax, Nova Scotia, Canada from October 11-15, 2022.
PepGen’s Senior Vice President, Head of Clinical Development, Michelle Mellion, M.D., will current information from PepGen’s Duchenne muscular dystrophy (DMD) candidate, PGN-EDO51, together with information evaluating the potential of PGN-EDO51 in non-human primates and evaluating PGN-EDO23 (mouse equal of PGN-EDO51) in mdx and wild-type mice.
“Our Enhanced Delivery Oligonucleotide (EDO) technology enables delivery of oligonucleotide levels in human muscle. In animal models of Duchenne muscular dystrophy, the EDO technology mediated very high levels of exon skipping and dystrophin restoration. We believe the combined results in human volunteers and animal models supports the potential of our platform,” Dr. Mellion mentioned.
“We are excited to present data at World Muscle Society Annual Conference on the heels of our recent announcement of data from our Phase 1 Healthy Normal Volunteer trial of PGN-EDO51, our lead candidate targeted to treat Duchenne muscular dystrophy, where we observed the highest levels of oligonucleotide delivery and exon skipping in a clinical study following a single dose. We remain committed to our mission to develop transformative therapies for people living with devastating neuromuscular diseases,” mentioned James McArthur, Ph.D., President and CEO of PepGen.
Poster Details:
Title: Unlocking the potential of oligonucleotide therapeutics for Duchenne muscular dystrophy by way of enhanced supply
- A single dose of PGN-EDO23 within the murine mdx DMD mannequin achieved as much as 93.1% exon skipping and 99.7% dystrophin expression in skeletal muscle, and 62.3% exon skipping and 25.7% dystrophin expression within the coronary heart
- Three doses of the medical product candidate, PGN-EDO51, in non-human primates achieved as much as 78% exon skipping in skeletal muscle and 24% exon skipping within the left ventricle of the center
- Repeat dosing of the medical product candidate, PGN-EDO51, in non-human primates demonstrated accumulation of exon skipped transcript with every dose in quadriceps and biceps
Presenter: Michelle Mellion, M.D., Senior Vice President, Head of Clinical Development
Date & Time: Poster displays out there all through the convention from October 12-15, 2022
Additional particulars may be discovered on the convention web site. The poster can be out there within the “Events & Presentations” part on PepGen’s web site following the assembly.
About Duchenne Muscular Dystrophy
Duchenne muscular dystrophy (DMD) is an X-linked recessive muscle-wasting illness that predominantly impacts males. This debilitating illness is attributable to genetic mutations within the gene encoding dystrophin, a protein crucial for wholesome muscle perform, and is likely one of the most prevalent uncommon genetic illnesses, with an incidence fee of roughly one in each 3,500 to five,000 male births. DMD is characterised by progressive muscle weak spot, which results in sufferers shedding the power to stroll, a lack of higher physique perform, cardiac points and difficulties respiration. DMD is invariably deadly by younger maturity. Despite important advances in therapies for this devastating illness, present therapies are restricted by poor supply to muscle tissue and have but to ascertain significant medical profit for DMD sufferers.
About PepGen
PepGen Inc. is a clinical-stage biotechnology firm advancing the next-generation of oligonucleotide therapies with the objective of remodeling the remedy of extreme neuromuscular and neurological illnesses. PepGen’s Enhanced Delivery Oligonucleotide (EDO) platform is based on over a decade of analysis and growth and leverages cell-penetrating peptides to enhance the uptake and exercise of conjugated oligonucleotide therapeutics. Using these EDO peptides, we’re producing a pipeline of oligonucleotide therapeutic candidates which might be engineered to focus on the foundation trigger of great illnesses. For extra data, go to www.pepgen.com or comply with PepGen on Twitter and LinkedIn.
Forward-Looking Statements
This press launch incorporates forward-looking statements throughout the that means of the Private Securities Litigation Reform Act of 1995, as amended. These statements could also be recognized by phrases resembling “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of those phrases or comparable expressions which might be meant to establish forward-looking statements. Any such statements on this press launch that aren’t statements of historic truth could also be deemed to be forward-looking statements. These forward-looking statements embody, with out limitation, statements about our medical and preclinical packages, product candidates, together with their deliberate growth and therapeutic potential, plans for future growth and medical trials in our packages, together with the deliberate initiation of a Phase 2a MAD trial of PGN-EDO51 in DMD sufferers, achievement of milestones, and company and medical/preclinical methods.
Any forward-looking statements on this press launch are based mostly on present expectations, estimates and projections solely as of the date of this launch and are topic to numerous dangers and uncertainties that might trigger precise outcomes to vary materially and adversely from these set forth in or implied by such forward-looking statements. These dangers and uncertainties embody, however aren’t restricted to that we might fail to efficiently full preclinical research and medical trials of our product candidates or to acquire regulatory approval for advertising and marketing of such merchandise; preliminary medical trial outcomes for a number of of our product candidates is probably not predictive of future trial outcomes for such candidates; our product candidates is probably not secure and efficient; there could also be delays in regulatory clearance or adjustments in regulatory framework which might be out of our management; we might not be capable of nominate new drug candidates throughout the estimated timeframes; our estimation of addressable markets of our product candidates could also be inaccurate; we may have extra funding earlier than the tip of our anticipated money runway and will fail to well timed increase such extra required funding; extra environment friendly opponents or more practical competing therapies might emerge; we could also be concerned in disputes surrounding using our mental property essential to our success; we might not be capable of appeal to and retain key workers and certified personnel; earlier-stage trial outcomes is probably not predictive of later stage trial outcomes; and we’re depending on third events for some or all features of our product manufacturing, analysis and preclinical and medical testing. Additional dangers regarding PepGen’s packages and operations are described in its most up-to-date quarterly report on Form 10-Q on file with the SEC. PepGen explicitly disclaims any obligation to replace any forward-looking statements besides to the extent required by legislation.
Investor Contact
Laurence Watts
Gilmartin Group
[email protected]
Media Contact
Gwendolyn Schanker
LifeSci Communications
[email protected]
